Would you continue adjuvant FOLFOX for a patient with stage III colon cancer and triple-vessel coronary artery disease who developed NSTEMI after the first cycle?

Topics: Gastrointestinal Cancers • Medical Oncology

If so, would you adjust 5-FU dosing?

Answer from: Medical Oncologist at Community Practice

This is a challenging scenario where the patient has existing triple vessel CAD and developed NSTEMI after 1st cycle. We all agree that 5-FU based therapy is the backbone for adjuvant therapy of stage III colon cancers. There are no clear cut guidelines in this case and management is per expert reco...

Comments

Medical Oncologist at Florida Cancer Specialists
Could you substitute capecitabine?

Medical Oncologist at Washington University/Barnes-Jewish Hospital
For patients with cardiac risk in whom chemotherap...

Medical Oncologist at UAB, Birmingham
Great questions. Capecitabine has been shown ...

Related Questions